Cancer Research
Newswire |
REHOVOT, Israel and JERSEY CITY, New Jersey, August 12 /PRNewswire/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release first quarter financial results on August 19, 2008, before the U.S. markets open. Rosetta Genomics will host a conference call with a simultaneous webcast to discuss these results at 8:30 a.m. ET on Tuesday, August 19.
To access the live conference call, U.S. and Canadian participants may dial 1-866-966-5335; international participants may dial +44-20-3023-4460. To access the 24-hour audio replay, U.S. and Canadian participants may dial 1-866-583-1035;…
Newswire |
SAN DIEGO, August 12 /PRNewswire/ --
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and corporate milestones.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)
Recent product and corporate highlights: -- Key clinical results from our Phase 1 trial of HspE7, a therapeutic treatment for patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer: * Completion of safety and tolerability assessment in Phase 1…
Newswire |
LOS ANGELES, California and GUANGZHOU, China, August 12 /PRNewswire/ --
- Major Threat Treatable With StatC(TM); FDA-Approved Drugs to Begin Testing in U.S. Animal Models
An internationally renowned avian influenza expert today hailed "encouraging and exciting" results from experiments conducted by his research team. This study demonstrated impressive efficacy of a novel statin/caffeine combination, StatC(TM) in the treatment and prevention of H5N1, H1N1 and H3N2 in a mouse model.
To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/canopusbiopharma/34441/
Dr.…
Newswire |
REHOVOT, Israel and JERSEY CITY, New Jersey, August 11 /PRNewswire/ --
- The Study Will Correlate the Results of Rosetta Genomics' MicroRNA-Based CUP Assay With Diagnostic Work Conducted at M.D. Anderson Cancer Center
- Data on the Company's MicroRNA-Based CUP Assay and its High Sensitivity and Accuracy was Recently Published in the April Issue of Nature Biotechnology
Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today the initiation of a clinical validation study with The University of Texas M. D. Anderson…
Researchers have discovered a central molecular switch in fruit fly embryos that opens new avenues for studying the causes of birth defects and cancer in humans. Writing about their study in the Aug. 12 Developmental Cell, scientists at Cincinnati Children's Hospital Medical Center determined the switch to be a main tuning mechanism for instructing cells whether to form sensory nerves or blood cells in different parts of the body.
The molecular switch occurs when two central control genes, Hox and Senseless (Sens), compete for influence to regulate genetic signals that instruct cells to…
Scientists from the Gladstone Institute of Cardiovascular Disease (GICD) and UCSF have identified a key regulatory factor that controls development of the human vascular system, the extensive network of arteries, veins, and capillaries that allow blood to reach all tissues and organs.
The research, published in the latest issue of Developmental Cell, may offer clues to potential therapeutic targets for a wide variety of diseases, such as heart disease or cancer, that are impacted by or affect the vascular system.
Researchers in laboratory of GICD Director Deepak Srivastava, MD, found that…
How do you know when a scientific problem is finished? Biologists have been cracking open the cell and studying its molecular insides for a very long time now. How much more is there to learn? Perhaps it seems obvious that we are still missing much: we can't cure cancer very well, for example. On the other hand, one could ask, what's really keeping us from curing cancer, a lack of basic understanding or insufficiently developed technology? Nowhere is this problem of defining a scientific endpoint more obvious than in the community of scientists who are focused on some of the most basic…
Scientists have discovered a new species of bacteria in the mouth. The finding could help scientists to understand tooth decay and gum disease and may lead to better treatments, according to research published in the August issue of the International Journal of Systematic and Evolutionary Microbiology.
"The healthy human mouth is home to a tremendous variety of microbes including viruses, fungi, protozoa and bacteria," said Professor William Wade from King's College London Dental Institute. "The bacteria are the most numerous: there are 100 million in every millilitre of saliva and more than…
Anyone who has ever tried smoking probably remembers that first cigarette vividly - it likely brought either a nasty coughing fit or a rush of pleasure - a "buzz."
A new study links those first experiences with smoking, and the likelihood that a person is currently a smoker, to a particular genetic variation.
The new finding also adds to growing suspicion surrounding the role of a particular nicotine-receptor gene in smoking-related behaviors and in lung cancer. Other researchers have already linked variations in the same genetic region to smokers' level of dependence on nicotine, to the…
Newswire |
KOBE, Japan, August 8 /PRNewswire/ --
Carna Biosciences, Inc. ("Carna") is pleased to announce the signing of a collaborative agreement with Caliper Life Sciences, Inc. USA ("Caliper") on August 6 (US Eastern Daylight Time). Carna will supply a set of discrete protein kinases aiding the expansion of Caliper's kinase profiling and assay development services, and ProfilerPro Kinase Selectivity Assay Kits. Caliper's products and services are widely used and highly regarded by leading pharmaceutical and biotech companies. The selection of Carna as a Preferred Provider enhances the visibility and…